In March 2024, the FDA approved the first over-the-counter continuous glucose monitors (CGMs), marking a quiet but significant shift in how we can track and understand our health. Devices like ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. DexCom (NasdaqGS:DXCM) is ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...

Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users understand their glucose ...

Dexcom launched its first over-the-counter continuous glucose monitor called Stelo on Monday. Users can buy a one-month supply online for $99, or sign up for an ongoing subscription at $89 a month.

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of ...

This week, Dexcom became the first medical device company to integrate generative AI into a continuous glucose monitor. The company added generative AI to its Stelo glucose monitor, which it began ...

Dexcom on Tuesday announced that its new over-the-counter continuous glucose monitor called Stelo has been cleared for use by the FDA. The new CGM is designed for patients with Type 2 diabetes who do ...

DexCom Inc. DXCM recently announced the availability of Stelo, the first over-the-counter (OTC) continuous glucose monitoring (CGM) biosensor in the United States. The biosensor is available for ...

Dexcom on Monday announced its new over-the-counter continuous glucose monitor Stelo is officially available for purchase in the U.S. Glucose is a type of sugar people receive from food, and it's the ...